DSDirkje Willemien Sommeijer

Dirkje Willemien Sommeijer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dirkje Willemien Sommeijer has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Felice N. van Erning

    Department of Surgery, Catharina Cancer Institute, Eindhoven, Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, Netherlands

    4 shared publications
  • Pascale J.M. Schafrat

    Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands; Department of Medical Oncology, Amsterdam UMC, Amsterdam, the Netherlands

    3 shared publications
  • Evelien Dekker

    Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

    2 shared publications
  • Louis Vermeulen

    Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC and University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Department of Medical Oncology, Amsterdam UMC, Amsterdam, the Netherlands

    2 shared publications
  • Miriam Koopman

    Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

    2 shared publications
  • Ruben S.A. Goedegebuure

    Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Prognostic significance of CK7, CK20, and CDX2 expression in small intestinal adenocarcinoma

    by P.J.M. Schafrat, J.D.G. Linssen, T.R. de Back, L.E. Nijman, M.C.S. van der Heijden, N.C.T. van Grieken, G. Kazemier, P. Drillenburg, M. Chalabi, F.N. van Erning, et al.

  • Open Access

    Adenocarcinoma of the small intestine cohort: prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer

    by Pascale J.M. Schafrat, Tim R. De Back, Felice N. Van Erning, Frederieke H. Van der Baan, Geraldine R. Vink, Miriam Koopman, Ruben S.A. Goedegebuure, Louis Vermeulen, Ignace H.J.T. De Hingh, Dirkje W. Sommeijer

    Background and purpose: Small intestinal adenocarcinoma (SIA) is a rare cancer with a poor prognosis. Optimal treatment strategies are unclear as biological understanding of the disease is limited and randomized controlled trials are lacking. Current management is based on protocols for other gastrointestinal cancers. Therefore, the AdenoCarcinoma of the Small Intestine (ACSI) cohort was initiated, a subcohort of the nationwide Prospective Dutch ColoRectal Cancer cohort (PLCRC) study. The ACSI cohort aims to provide a large-scale, prospective SIA cohort, where clinical and molecular data will be combined to improve knowledge on tumor biology, treatment responsiveness, disease outcome and patient reported outcomes (PROs). Patient/material and methods: All adult SIA patients in the Netherlands are eligible for inclusion. Nationwide inclusion is facilitated by 68 hospitals. Clinical data are collected, as well as optional PROs, pathology- and blood samples.Results: Until June 2025, 143 patients have been enrolled. Data of the first 105 patients show a median age of 65 years (interquartile range 58–73) at diagnosis with a slight male predominance (60%). Most tumors are located in the duodenum (57%) and 27% of patients present with stage IV disease, with a majority having single-site metastases (64%). Primary tumor resection is performed in 80%, while systemic treatment is administered in 42%. Four patients did not receive any anti-tumor treatment (14%). Mismatch repair deficiency is detected in 28% of patients.Interpretation: The ACSI cohort enables structured national collection of clinical data, tumor samples and PROs of SIA patients. These data provide a valuable source for further research and improvement of care for this patient group.


  • Open Access

    Malignancies of the small intestine: incidence and trends in a nationwide registry

    by Pascale J.M. Schafrat, Felice N. van Erning, Koos Zwinderman, Evelien Dekker, Arantza Farina Sarasqueta, Judith de Vos-Geelen, Stefan A.W. Bouwense, Ruben S.A. Goedegebuure, Louis Vermeulen, Ignace H.J.T. de Hingh, et al.


  • Open Access

    Predisposing conditions in patients with small intestinal adenocarcinomas in the Netherlands: A 20‐year nationwide cohort study

    by Jasmijn D. G. Linssen, Pascale J. M. Schafrat, Tim R. de Back, Felice N. van Erning, Monique E. van Leerdam, Evelien Dekker, Louis Vermeulen, Ignace H. J. T. de Hingh, Dirkje W. Sommeijer

    Small intestinal adenocarcinomas (SIAs) are associated with predisposing conditions, including inflammatory bowel disease (IBD) and celiac disease, but also genetic syndromes such as Lynch syndrome (LS) and familial adenomatous polyposis (FAP). This nationwide cohort study investigated the incidence of genetic and non‐genetic predisposing conditions in SIA and their influence on tumor characteristics and clinical features. Data were obtained from the Netherlands Cancer Registry. The incidence, characteristics, and clinical features per predisposing condition were analyzed in 2697 SIA patients diagnosed from 1999 through 2019. Of all SIA patients, 5.6% were known to have a genetic predisposing syndrome, of whom 4.0% had LS and 1.6% had a polyposis syndrome. In addition, 6.8% of SIA patients had a non‐genetic predisposing condition: 3.9% IBD and 2.9% celiac disease. SIAs of patients with such predisposing syndromes or conditions were diagnosed at a younger age and earlier stage and affected the duodenum less often as compared to sporadic SIA patients. Both genetic and non‐genetic predisposing conditions were associated with significantly better overall survival (OS) compared to sporadic SIA: sporadic SIA (median OS: 13.0 months, 95% CI: 11.8–14.2), LS (213.1 months, 99.3–NA), polyposis syndromes (61.3 months, 19.7–NA), IBD (29.5 months, 20.3–69.8), and celiac disease (50.4 months, 24.6–124.7). This nationwide cohort study shows significant differences between SIA with and without predisposing conditions and highlights the need for research on underlying molecular mechanisms to improve outcomes of SIA patients.


  • Open Access

    Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology

    by Richard M Goldberg, Richard Adams, Marc Buyse, Cathy Eng, Axel Grothey, Thierry André, Alberto F Sobrero, Stuart M Lichtman, Al B Benson, Cornelis J A Punt, et al.

    Meta-analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an increasingly important use is in clarifying trials methodology, for instance in the selection of endpoints, as discussed in this review. In oncology, the Aide et Recherche en Cancérologie Digestive (ARCAD) Metastatic Colorectal Cancer Database is a leader in the use of IPD-based meta-analysis in methodological research. The ARCAD database contains IPD from more than 38 000 patients enrolled in 46 studies and continues to collect phase III trial data. Here, we review the principal findings of the ARCAD project in respect of endpoint selection and examine their implications for cancer trials. Analysis of the database has confirmed that progression-free survival (PFS) is no longer a valid surrogate endpoint predictive of overall survival in the first-line treatment of colorectal cancer. Nonetheless, PFS remains an endpoint of choice for most first-line trials in metastatic colorectal cancer and other solid tumors. Only substantial PFS effects are likely to translate into clinically meaningful benefits, and accordingly, we advocate an oncology research model designed to identify highly effective treatments in carefully defined patient groups. We also review the use of the ARCAD database in assessing clinical response including novel response metrics and prognostic markers. These studies demonstrate the value of IPD as a tool for methodological studies and provide a reference point for the expansion of this approach within clinical cancer research.


  • Open Access

    The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?

    by A. van der Hout, K. Holtmaat, F. Jansen, B. I. Lissenberg-Witte, C. F. van Uden-Kraan, G. A. P. Nieuwenhuijzen, J. A. Hardillo, R. J. Baatenburg de Jong, N. L. Tiren-Verbeet, D. W. Sommeijer, et al.

    Oncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and ta...


  • PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.

    by Michael Friedlander, Katrin Marie Sjoquist, Dirkje Willemien Sommeijer, Lisa Bailey, Julie Martyn, Kim Gillies, Linda R. Mileshkin, Rachel O'Connel, Val Gebski, Michelle Margaret Vaughan, et al.

    TPS5614 Background: Many gynaecological cancers of different pathological type express estrogen and/or progesterone hormone receptors (ER/PR). Reports of tumour response and clinical benefit with hormonal therapies show variable rates of activity. There is a need to prospectively study the role of aromatase inhibitors in women with potentially hormone responsive recurrent gynaecological cancers to establish response rates, clinical benefit, quality of life (QoL) and identify predictors of response. Methods: PARAGON is phase II Gynecologic Cancer InterGroup trial lead by the Australia New Zealand Gynaecological Oncology Group, Cancer Research UK and the Belgian Gynaecological Oncology Group. The study is designed to facilitate research in rare tumours. The protocol allows postmenopausal women with recurrent gynaecological cancers to enrol into one of 7 subgroups; epithelial ovarian cancer (EOC) with only rising CA125 after first line chemotherapy, platinum resistant/refractory EOC, low grade EOC, endometrial carcinomas, endometrial stromal sarcomas, miscellaneous sarcomas and granulosa cell tumours and other sex cord stromal tumours. ER/PR positivity must be confirmed by immunohistochemistry. Each subgroup will enrol 25-50 patients with defined stopping rules based on response and reviewed by independent data monitoring committee (IDMC). Eligible patients receive 1 mg anastrozole daily until disease progression or unacceptable toxicity. Primary objective: clinical benefit (partial or complete response or stable disease). Secondary objectives: progression free survival, response duration, QoL, toxicity. Blood and tumour samples are being collected for translational studies and confirmation of ER/PR positivity. Recruitment commenced in 2011 in Australia, New Zealand and the United Kingdom. One hundred and fourteen of 350 planned patients have been enrolled to January 2013. In November 2012 IDMC recommended continuing recruitment to the EOC with rising Ca125 only and resistant/refractory subgroups based on review of activity outcomes for the first 25 patients. The trial will open in Belgium in April 2013. ACTRN12610000796088 Clinical trial information: 12610000796088.